MTCO1P35

Across TCGA pan-cancer cohorts, MTCO1P35 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated MTCO1P35 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MTCO1P35 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCO1P35 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

BLCA, UCEC, and STAD are the cancer types where MTCO1P35 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	IV	0.074	0.599	<.001	36	view →
UCEC	OS	Tertile	II,III,IV	0.090	0.542	.002	36	view →
STAD	DFS	Tertile	II,III,IV	0.232	0.551	.023	15	view →
LUAD	DFS	Tertile	All	1.000	0.333	.028	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTCO1P35–BLCA (OS)

Open the BLCA breakdown →